Health Care · Laboratory Analytical Instruments

BIO Bio-rad Laboratories Inc SEC Filings & Insider Trading Activity 2026

company
CIK 1220892 filings

BIO at a glance

Bio-rad Laboratories Inc (BIO, SEC CIK 12208) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Bio-rad Laboratories Inc (BIO) reported revenue of $2.6 billion (up 0.7% from FY2024) and net income of $759.9 million. Diluted EPS was $27.85.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Bio-rad Laboratories Inc (BIO) shares worth $2.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by ENLOE COURTNEY C on November 10, 2026 of 902 shares at $386.17 per share.
  • In the last 90 days, BIO insiders reported 0 open-market purchases ($0) and 3 open-market sales ($1.2M) on Form 4, a net sale of $1.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.6B
+0.7% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$1.2M
13F holders
36 funds
$2.6B · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added AI risk: generative AI may expose confidential information or generate infringing content amid evolving regulation
  • Most material market update: aggressive pricing in multi-year public tenders, reducing annual tender opportunities and pressuring margins
  • Regulatory risk: future LDT legislation could impose FDA-style requirements on customers using Bio-Rad life science products
  • Operational risk: Middle East conflicts disrupting logistics, fuel costs and regional sales
  • Financial risk: $1.2 billion debt, including $400 million due March 2027 and $800 million due March 2032

Management Discussion & Analysis

  • Q3 revenue $656.4M, up 0.5% YoY from $653.0M, driven by Clinical Diagnostics
  • Clinical Diagnostics revenue $401.8M, up 2.7% YoY; Life Science $254.6M, down 2.8%
  • Gross margin 50.1% vs 52.6% YoY; SG&A margin 39.2% vs 31.7%
  • Operating cash flow $303.2M vs $367.3M; cash, equivalents and short-term investments $1.66B
  • Restructuring charges $77.6M; expected annual savings $30M to $35M by end-2027, with EMEA headwinds continuing

AI summary of the BIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item EX-99.2: Item EX-99.2

  • Q3 revenue $656M, up 0.5% reported and 0.7% currency-neutral, indicating modest top-line growth
  • GAAP operating margin (7.6%), pressured by $77M restructuring and $50M intangible impairment charges

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 4, 2026
  • Supplemental Earnings Presentation provides additional investor detail under Item 7.01

Item 7.01: Regulation FD Disclosure

  • Supplemental earnings presentation covers Bio-Rad’s quarter ended September 30, 2026
  • Investor-relevant financial detail is contained in Exhibit 99.2 and the company’s Investor Relations website

Item EX-99.1: Item EX-99.1

  • Q3 revenue $656.4M, up 0.5% reported and 0.7% currency-neutral, signaling stabilization after prior declines
  • Clinical Diagnostics revenue $401.8M, up 2.8% currency-neutral, offsetting Life Science’s 2.4% decline
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Bio-Rad announced financial results for the quarter ended June 30, 2026
  • Supplemental Earnings Presentation referenced under Item 7.01, with detailed results in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Supplemental earnings presentation covers Bio-Rad’s quarter ended June 30, 2026
  • Materials available through Bio-Rad Investor Relations and Exhibit 99.2

Item 2.05: Costs Associated with Exit or Disposal Activities

  • Strategy-driven restructuring initiated July 31, 2026, targeting global operations and functions
  • Estimated pre-tax charges of approximately $80 million to $90 million, primarily termination benefits and severance

Item EX-99.1: Item EX-99.1

  • Q2 revenue $651.0M, essentially flat year over year; currency-neutral revenue declined 1.9%
  • Life Science revenue $252.0M, down 4.1% reported and 5.1% currency-neutral amid academic research weakness

AI summaries of BIO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BIO

Don't miss the next BIO filing

  • Alerts as it files. A push when BIO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BIO, by share count.
  • Ask anything. An AI agent that reads every BIO filing and answers with sources.

BIO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
ENLOE COURTNEY CSellNov 10, 2026$386.17
BARRY JAMESSellNov 9, 2026$385.63
DiVincenzo Jonathan P.SellNov 9, 2026$390.47
DiVincenzo Jonathan P.FOct 24, 2026$369.95
DiVincenzo Jonathan P.MOct 24, 2026-
DiVincenzo Jonathan P.MOct 24, 2026-
EVRAN SEDATFOct 20, 2026$354.50
EVRAN SEDATMOct 20, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.6B$2.6B
Gross Profit-$1.4B$1.3B
Operating Income-$269.0M$47.2M
Net Income--$1.8B$759.9M
Gross Margin-53.7%51.9%
Op. Margin-10.5%1.8%
Net Margin--71.9%29.4%
Balance Sheet
Total Assets$12.3B$9.4B$10.6B
Equity$8.7B$6.6B$7.5B
ROE--28.1%10.2%
Per Share
EPS-$-65.36$27.85
Cash Flow
Operating CF-$455.2M$532.2M
CapEx-$165.6M$157.6M

Source: XBRL data in Bio-rad Laboratories Inc (BIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BIO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BIO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$2.63B
Q2 202636$2.09B
Q1 202637$1.96B
Q4 202533$2.01B
Q3 202534$1.94B
Q2 202531$1.71B
Q1 202529$1.33B
Q4 202428$1.57B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 264 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BIO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 27, 2026--
4Oct 22, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026-
4Jul 28, 2026--
4May 13, 2026-
8-KApr 30, 2026--
10-QApr 30, 2026-

Related Health Care companies

All Health Care →

BIO SEC filings: frequently asked questions

Are BIO insiders buying or selling?

In the last 90 days, Bio-rad Laboratories Inc (BIO) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $1.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BIO stock?

As of September 30, 2026, the largest Bio-rad Laboratories Inc (BIO) holders among the 13F filers tracked by SignalX were BlackRock ($657.3 million), Dimensional Fund Advisors ($334.6 million), Vanguard Capital Management LLC ($312.4 million), Vanguard Portfolio Management LLC ($306.5 million), State Street Corp ($217.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BIO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Bio-rad Laboratories Inc (BIO) reported revenue of $2.6 billion (up 0.7% from FY2024) and net income of $759.9 million. Diluted EPS was $27.85. The figures come from the XBRL data in the 10-K.

What did BIO report in its latest 8-K?

Bio-rad Laboratories Inc (BIO) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 revenue $656M, up 0.5% reported and 0.7% currency-neutral, indicating modest top-line growth.

What are the latest BIO SEC filings?

Bio-rad Laboratories Inc (BIO) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.

What is BIO's SEC CIK number?

Bio-rad Laboratories Inc (BIO)'s SEC Central Index Key (CIK) is 12208. EDGAR lists every BIO filing under that number.

Ask anything about BIO

The research agent reads BIO's filings, financials, insider trades and 13F holders, then answers with sources.